What we do

Personalized and Precision Medicine can transform lives, but its potential benefits have not yet been fully realized.

Why is that? Because:
The precision medicine landscape is rapidly changing and fragmented.
Efforts to expand it are piecemeal and disconnected.
Best practices are hard to identify, and lack of standardization on national and global levels is a challenge.
Patients are often unaware that better treatments may exist, and are not able to discuss these options with their doctors.
Even where treatments are available, barriers to access may prevent that treatment from being offered to patients.
Healthcare professionals may need support in interpreting data or in making clinical decisions.

As a result, patients do not benefit from optimal treatment, with a health, societal and economic impact.

The From Testing to Targeted Treatments program (FT3) aims to respond to these challenges, through a co-creation approach, building with patients for patients.

The Goal

Accelerate the benefits of precision medicine by generating better evidence, creating awareness and building the conditions for better access to targeted medicine in oncology and beyond.

How the From Testing to Targeted Treatments program is delivering on its promise


Landscape Mapping & Need Analysis

Understand the environment, barriers & map existing activities to inform strategic planning and identify synergies to build on.


Co-creation & Collaboration

Open collaboration globally to shape strategy and guide production for useful and impactful outcomes. Enable sustainable change by bringing together and supporting all stakeholder types in the whole precision medicine system.



Iteratively consult, test and improve solutions in real-life context, using FT3 community to reach a wider audience.


Integration & Optimization

Integrated & optimized global resources & solutions available to all stakeholders, bringing together learnings and best practices from across the precision medicine community.

Members have identified 5 strategic priorities that are being addressed through 3 co-creation working groups. 

Provide education and tools to support patient empowerment and informed decision-making.

Patient and HCP Education and Awareness Working Group

Support data & evidence development to demonstrate benefits of PM on patient outcomes and put in place a data governance structure

Data and Evidence Working Group

Build the accessibility conditions for PM to become a reality for patients that would benefit it

Systemic Barriers & Opportunities Working Group

Transversal program priorities:

Build the value case for PM, starting with proven clinical areas, and raise awareness to increase support & resourcing

Build a world class governance and the foundation for trust, credibility, agile growth, and impact

Keep up to date with the latest developments from the FT3 Program

We don’t spam. Just key info at the right time.